Immunovant (IMVT) Interest Expenses (2019 - 2026)

Immunovant's Interest Expenses history runs 8 years deep, the most recent figure standing at $252000.0 for Q1 2026.

• Quarterly Interest Expenses fell 99.88% year-over-year to $252000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $252000.0 (down 99.88% YoY) and the FY2026 annual result came in at $312.0 million, up 42.6% from the prior year.
• Interest Expenses was $252000.0 for Q1 2026 at Immunovant, down from $117.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $429.4 million in Q4 2023 and bottomed at $13000.0 in Q2 2022.
• A 5-year average of $127.4 million and a median of $114.6 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses jumped 1032776.92% — and 2026, when it tumbled 99.88%.
• Immunovant's Interest Expenses stood at $114.6 million in 2022, then jumped by 274.81% to $429.4 million in 2023, then sank by 58.34% to $178.9 million in 2024, then sank by 34.49% to $117.2 million in 2025, then sank by 99.78% to $252000.0 in 2026.
• Business Quant data shows IMVT's Interest Expenses at $252000.0 in Q1 2026, $117.2 million in Q4 2025, and $48.1 million in Q3 2025.